CTLA4 and hepatocellular carcinoma: In this study, we profiled ILCs from peripheral blood mononuclear cells (PBMCs) from HCC patients and studied the effect of anti-CTLA-4 antibody (tremelimumab) as well as anti-PD-L1 antibody (durvalumab) on these cells.